Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 432-440

  Kolbrich, Erin A ^a   Goodwin, Robert S ^a   Gorelick, David A ^b   Hayes, Robert J ^c   Stein, Elliot A ^c   Huestis, Marilyn A ^a,c  

^a Chemistry and Drug Metabolism   (United States)

^b Office of the Scientific Director   (Italy)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ADRENERGIC RECEPTOR AFFECTING AGENT; PSYCHEDELIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; ADOLESCENT; BODY TEMPERATURE; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HEMODYNAMICS; HOSPITAL PATIENT; METABOLISM; ORAL DRUG ADMINISTRATION; PERCEPTION; PHYSIOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; BODY TEMPERATURE; CARDIOVASCULAR PHYSIOLOGY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HEART RATE; HEMODYNAMICS; HUMANS; INPATIENTS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PERCEPTION; QUESTIONNAIRES;

EID: 54449098078     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817ef470     Document Type: Article

References (38)

1. de la Torre R, Faire M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26:137-144.
2. Ropero-Miller JD, Goldberger BA. Recreational drugs: current trends in the 90s. Toxicology. 1998;18:727-746.
3. Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986;18:319-327.
4. Hall AP, Henry JA. Acute toxic effects of 'ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96:678-685.
5. Lester SJ, Baggott M, Welm S, et al. Cardiovascular effects of 3,4- methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:969-973.
6. Vollenweider FX, Gamma A, Liechti M, et al. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy")in MDMA-naive healthy volunteers. Neuropsychopharmacology. 1998;19:241-251.
7. Harris DS, Baggott M, Mendelson JH, et al. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2002;162:396-405.
8. de la Torre R, Farre M, Roset PN, et al. Pharmacology of MDMA in humans. Ann NY Acad Sci. 2000;914:225-237.
9. Downing J. The psychological and physiological effects of MDMA on normal volunteers. JPsychoactive Drugs. 1986;18:335-340.
10. Cami J, Farre M, Mas M, et al. Human pharmacology of 3,4- methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol. 2000;20(4):455-466.
11. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects ofMDMA. Psychopharmacology. 2001;154:161-168.
12. Siegel RK. MDMA. Nonmedical use and intoxication. J Psychoactive Drugs. 1986;18:349-354.
13. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, meth- amphetamine, and their N-alkyl derivatives. Ther Drug Monit. 2002;24:277-289.
14. Segura M, Ortuno J, Farre M, et al. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol. 2001;14:1203-1208.
15. de la Torre R, Farre M, Ortuno J, et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. J Clin Pharmacol. 2000;49:104-109.
16. Ortuno J, Pizarro N, Farre M, et al. Quantification of 3,4-methylene-dioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl. 1999;723:221-232.
17. Fallon JK, Kicman AT, Henry JA, et al. Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (ecstasy) in humans. Clin Chem. 1999;45:1058-1069.
18. Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136-145.
19. Navarro M, Pichini S, Farre M, et al. Usefulness of saliva for measurement of 3,4-methylenedioxymehamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem. 2001;47:1788-1795.
20. Kolbrich EA, Goodwin RS, Gorelick DA, et al. Plasma pharma-cokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit. 2008;30:320-332.
21. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, et al. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('ecstasy'). Toxicol Lett. 2000;112-113:133-142.
22. Kolbrich EA, Lowe RH, Huestis MA. Two-dimensional gas chromatog- raphy/electron impact-mass spectrometry with cryofocusing for the sensitive, specific and simultaneous quantification of 3,4-methylene-dioxymethamphetamine (MDMA, 3,4-methylenedioxyampheta\mine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 4-hydroxy- 3-methoxyamphetamine (HMA), and 3,4- methylenedioxyethylamphetamine (MDEA) in human plasma. Clin Chem. 2008;54:379-387.
23. Farre M, Abanades S, Roset PN, et al. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther. 2007;323:954-962.
24. Farre M, de la Torre R, Mathuna BO, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl). 2004;173:364-375.
25. Patel MM, Belson MG, Wright D, et al. Methylenedioxymethamphetamine (ecstasy)-related myocardial hypertrophy: an autopsy study. Resuscitation. 2005;66:197-202.
26. Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylene- dioxymethamphetamine ("ecstasy") in healthy volunteers. J Psychopharmacol. 2000;14:269-274.
27. Parrott AC. MDMA in humans: factors which affect the neuropsycho- biological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. JPsychopharmacol. 2006;20:147-163.
28. Bordo DJ, Dorfman MA. Ecstasy overdose: rapid cooling leads to successful outcome. Am J Emerg Med. 2004;22:326-327.
29. Gill JR, Hayes JA, deSouza IS, et al. Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. J Forensic Sci. 2002; 47:121-126.
30. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-meth- ylenedioxymethamphetamine ("ecstasy"). Lancet. 1992;340:384-387.
31. Freedman RR, Johanson CE, Tancer ME. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psycho-pharmacology (Berl). 2005;183:248-256.
32. Boulant JA. Neuronal basis of Hammel's model for set-point thermo-regulation. JAppl Physiol. 2006;100:1347-1354.
33. Wood JM, Garth D, Grounds G, et al. Pupil dilatation does affect some aspects of daytime driving performance. Br Ophthalmol. 2003;87:1387-1390.
34. Kunsman GW. Human performance toxicology. In: Levine B, ed. Principles of Forensic Toxicology. Washington, DC: American Association for Clinical Chemistry, Inc; 1999:13-30.
35. Hernandez-Lopez C, Farre M, Roset PN, et al. 3,4-Methylenedioxyme- thamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther. 2002;300:236-244.
36. Tancer ME, Johanson CE. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2001;65:97-101.
37. Tancer M, Johanson CE. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2007;189:565-573.
38. Moore KA, Mozayani A, Fierro MF, et al. Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenediox- yamphetamine (MDA) stereoisomers in a fatal poisoning. Forensic Sci Int. 1996;83:111-119.